Avenue Therapeutics, Inc. (ATXI)

USD 1.84

(10.84%)

Market Cap (In USD)

3.77 Million

Revenue (In USD)

-

Net Income (In USD)

-10.37 Million

Avg. Volume

47.47 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
1.6-26.475
PE
-
EPS
-
Beta Value
-0.179
ISIN
US05360L3042
CUSIP
05360L205
CIK
1644963
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Alexandra MacLean M.D.
Employee Count
-
Website
https://www.avenuetx.com
Ipo Date
2017-06-27
Details
Avenue Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes products primarily for use in the acute/intensive care hospital setting. Its product candidate is intravenous Tramadol, a synthetic dual-acting opioid, which is in Phase III clinical trials for the treatment of post-operative acute pain. The company was incorporated in 2015 and is based in New York, New York.